Abbott Secures Semaglutide Distribution Rights in India. Abbott has partnered with Novo Nordisk India to distribute Extensior, a semaglutide injection for Type 2 diabetes treatment. This marks the second exclusive distribution deal for Novo's semaglutide portfolio in India, following Emcure Pharma's earlier agreement. Extensior will be available in 0.25mg, 0.5mg, and 1mg doses at competitive pricing. The move reflects Novo Nordisk's strategy to expand market access beyond premium urban clinics. With semaglutide sales already exceeding Rs 1,000 crore and patent expiry approaching next month, generic competition is expected to reduce prices by 50-60 percent, significantly expanding the diabetes and weight-loss drug market across India.
